MCID: NLD001
MIFTS: 54

Nail Disease

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Nail Disease

MalaCards integrated aliases for Nail Disease:

Name: Nail Disease 12 6 15
Nail Diseases 44 45 74
Abnormality of the Nail 30 6

Classifications:



External Ids:

Disease Ontology 12 DOID:4123
ICD9CM 36 703 703.9
MeSH 45 D009260
SNOMED-CT 69 17790008
UMLS 74 C0027339

Summaries for Nail Disease

MedlinePlus : 44 Your toenails and fingernails protect the tissues of your toes and fingers. They are made up of layers of a hardened protein called keratin, which is also in your hair and skin. The health of your nails can be a clue to your overall health. Healthy nails are usually smooth and consistent in color. Specific types of nail discoloration and changes in growth rate can be signs of lung, heart, kidney, and liver diseases, as well as diabetes and anemia. White spots and vertical ridges are harmless. Nail problems that sometimes require treatment include Bacterial and fungal infections Ingrown nails Tumors Warts Keeping your nails clean, dry, and trimmed can help you avoid some problems. Do not remove the cuticle, which can cause infection.

MalaCards based summary : Nail Disease, also known as nail diseases, is related to nail disorder, nonsyndromic congenital, 4 and paronychia, and has symptoms including pruritus, exanthema and clubbing of nail. An important gene associated with Nail Disease is FZD6 (Frizzled Class Receptor 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ethanol and Phenol have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and kidney, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Disease Ontology : 12 An integumentary system disease that is located in nail.

Wikipedia : 77 A nail disease or onychosis is a disease or deformity of the nail. Although the nail is a structure... more...

Related Diseases for Nail Disease

Diseases in the Nail Disease family:

Nail Disorder, Nonsyndromic Congenital, 6 Nail Disorder, Nonsyndromic Congenital, 2
Nail Disorder, Nonsyndromic Congenital, 3 Nail Disorder, Nonsyndromic Congenital, 1
Nail Disorder, Nonsyndromic Congenital, 5 Nail Disorder, Nonsyndromic Congenital, 4
Nail Disorder, Nonsyndromic Congenital, 7 Nail Disorder, Nonsyndromic Congenital, 8
Nail Disorder, Nonsyndromic Congenital, 9 Nail Disorder, Nonsyndromic Congenital, 10

Diseases related to Nail Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
# Related Disease Score Top Affiliating Genes
1 nail disorder, nonsyndromic congenital, 4 31.3 RSPO4 ZNF519
2 paronychia 10.9
3 tooth agenesis, selective, 4 10.8
4 nail-patella syndrome 10.8
5 keratosis palmoplantaris striata ii 10.8
6 tinea unguium 10.7
7 nail disorder, nonsyndromic congenital, 1 10.3 AIRE FZD6
8 acute generalized exanthematous pustulosis 10.2 IL17A IL17F
9 immunodeficiency 17 10.2 CARD9 STAT1
10 psoriatic arthritis 10.2
11 arthritis 10.2
12 axillary adenitis 10.1 IL12RB1 STAT1
13 psoriasis 10.1
14 autoimmune polyendocrine syndrome type 1 10.1 AIRE IL17A
15 phaeohyphomycosis 10.1 CARD9 STAT1
16 nasopharyngitis 10.1 IL17A IL17RA
17 candidiasis, familial, 2 10.1 CARD9 CLEC7A
18 subcutaneous mycosis 10.0 CARD9 CLEC7A
19 familial candidiasis 10.0 CARD9 IL17F IL17RA
20 chromoblastomycosis 10.0 CARD9 CLEC7A
21 stromal keratitis 10.0 CCR6 IL17A IL17RA
22 coccidioidomycosis 9.9 CARD9 CLEC7A STAT1
23 primary systemic mycosis 9.9 CARD9 CLEC7A IL17A
24 hidradenitis suppurativa 9.9 IL12RB1 IL17A
25 enthesopathy 9.8
26 hidradenitis 9.8 IL12RB1 IL17A
27 cleft palate, isolated 9.7
28 pemphigus vulgaris, familial 9.7
29 pemphigus vulgaris 9.7
30 lymphoma 9.7
31 pustulosis of palm and sole 9.7
32 dermatophytosis 9.7
33 pemphigus 9.7
34 cleft lip 9.7
35 opportunistic mycosis 9.3 AIRE CARD9 CLEC7A IL17A IL17RA STAT1
36 chronic mucocutaneous candidiasis 9.2 AIRE CARD9 CLEC7A IL17A IL17F IL17RA
37 candidiasis 9.2 AIRE CARD9 CLEC7A IL17A IL17F IL17RA

Graphical network of the top 20 diseases related to Nail Disease:



Diseases related to Nail Disease

Symptoms & Phenotypes for Nail Disease

UMLS symptoms related to Nail Disease:


pruritus, exanthema, clubbing of nail

GenomeRNAi Phenotypes related to Nail Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CCR6 CLEC7A EGFR FZD6 IL17A STAT1

MGI Mouse Phenotypes related to Nail Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 AIRE CARD9 CCR6 CLEC7A EGFR IL12RB1
2 homeostasis/metabolism MP:0005376 9.85 AIRE CARD9 CCR6 CLEC7A EGFR IL12RB1
3 digestive/alimentary MP:0005381 9.8 AIRE CLEC7A EGFR IL17A IL17F STAT1
4 immune system MP:0005387 9.7 AIRE CARD9 CCR6 CLEC7A EGFR IL12RB1
5 respiratory system MP:0005388 9.1 AIRE CLEC7A EGFR IL17A IL17F IL17RA

Drugs & Therapeutics for Nail Disease

Drugs for Nail Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Phenol Approved, Experimental Phase 4,Not Applicable 108-95-2 996
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
4
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2 29342-05-0 2749
5
Amorolfine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 78613-35-1
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
7
Efinaconazole Approved Phase 4,Phase 3,Not Applicable 164650-44-6
8
carbamide peroxide Approved Phase 4,Phase 3,Not Applicable 124-43-6
9
Bifonazole Approved, Investigational Phase 4,Phase 3,Not Applicable 60628-96-8 2378
10
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91161-71-6 5402 1549008
11
Polihexanide Approved, Investigational Phase 4 28757-47-3
12
Etanercept Approved, Investigational Phase 4,Phase 3 185243-69-0
13
Lenograstim Approved, Investigational Phase 4 135968-09-1
14
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
15
Docetaxel Approved, Investigational Phase 4,Phase 3,Not Applicable 114977-28-5 148124
16
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
17
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
18
Apremilast Approved, Investigational Phase 4,Phase 2 608141-41-9 11561674
19
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
20
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
21
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
22
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
24
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
25 Anti-Infective Agents, Local Phase 4,Not Applicable
26 Central Nervous System Depressants Phase 4
27 Chlorhexidine gluconate Phase 4
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Disinfectants Phase 4
30 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
35 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Keratolytic Agents Phase 4,Not Applicable
37 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
42 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1,Not Applicable
43 Antiparasitic Agents Phase 4,Phase 2,Not Applicable
44 Antiprotozoal Agents Phase 4,Phase 2,Not Applicable
45 Hypoglycemic Agents Phase 4
46 Biguanides Phase 4
47 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
49 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
50 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 144)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Lavage With Alcohol - Chlorhexidine for Chemical Matricectomy Unknown status NCT01844141 Phase 4 70% alcohol;70% alcohol - 0.5% clorhexidine
2 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
3 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
4 Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery Completed NCT01330706 Phase 4 Polihexanide
5 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
6 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
7 Study Evaluating the Effect of Jublia on Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
8 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
9 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
10 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
11 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
12 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
13 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
14 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
15 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
16 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
17 Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
18 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Recruiting NCT03280927 Phase 4 Jublia®
19 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
20 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Active, not recruiting NCT02812771 Phase 4 Efinaconazole
21 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
22 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease Not yet recruiting NCT03263624 Phase 4 Tazarotene Cream 0.1%
23 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
24 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
25 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
26 Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer Completed NCT00925418 Phase 3
27 Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
28 Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails Completed NCT00999687 Phase 2, Phase 3 Indigo Naturalis Extract in Oil
29 Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis Completed NCT02376790 Phase 3 Etanercept;Methotrexate;Placebo to Etanercept;Placebo to Methotrexate
30 Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
31 Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population Completed NCT02547701 Phase 3 P-3058
32 Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
33 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
34 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
35 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
36 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
37 PinPointe FootLaser for the Treatment of Onychomycosis Completed NCT00935649 Phase 2, Phase 3
38 Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
39 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
40 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
41 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
42 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Active, not recruiting NCT03168841 Phase 3 Efinaconazole Topical
43 Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
44 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
45 Antifungal Drugs in Treatment of Onychomycosis Not yet recruiting NCT03171584 Phase 3 Terbinafine
46 Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
47 Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Terminated NCT01208129 Phase 3 NAB001;Placebo control
48 Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
49 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
50 Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis Unknown status NCT01528813 Phase 2 Amorolfine lacquer

Search NIH Clinical Center for Nail Disease

Cochrane evidence based reviews: nail diseases

Genetic Tests for Nail Disease

Genetic tests related to Nail Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Nail 30

Anatomical Context for Nail Disease

MalaCards organs/tissues related to Nail Disease:

42
Skin, Lung, Kidney, Liver, Heart, Testes, Eye

The Foundational Model of Anatomy Ontology organs/tissues related to Nail Disease:

20
Nail

Publications for Nail Disease

Articles related to Nail Disease:

(show top 50) (show all 77)
# Title Authors Year
1
MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response. ( 29531786 )
2018
2
The microvascular and morphostructural changes of nails in psoriatic patients with nail disease; a link between ultrasound and videocapillaroscopy findings in the nailfold. ( 29730685 )
2018
3
The microbial flora of taxane therapy-associated nail disease in cancer patients. ( 29447679 )
2018
4
Rare Variant of Ankyloblepharon-ectodermal Defect-cleft Lip/Cleft Palate Syndrome: Curly Hair-ankyloblepharon-nail Disease Syndrome. ( 29440852 )
2018
5
Reply to: "The microbial flora of taxane therapy-associated nail disease in cancer patients". ( 29447686 )
2018
6
Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. ( 30246363 )
2018
7
Hair and nail diseases in the mature patient. ( 29566920 )
2018
8
Biotin for the treatment of nail disease: what is the evidence? ( 29057689 )
2017
9
Pediatric nail diseases: clinical pearls. ( 28319636 )
2017
10
Nail unit ultrasound: a complete guide of the nail diseases. ( 28900518 )
2017
11
Detection of subclinical ultrasound enthesopathy and nail disease in patients at risk of psoriatic arthritis. ( 27932277 )
2016
12
Intralesional Injection for Inflammatory Nail Diseases. ( 26808185 )
2016
13
Nail Disease for the Primary Care Provider. ( 26476249 )
2015
14
Optimal management of nail disease in patients with psoriasis. ( 29387579 )
2015
15
Ultrasound in the management of nail disease. ( 26895940 )
2015
16
Clinical photography of nail diseases: a simple method to include all fingernails in a frame. ( 25497942 )
2015
17
UV-curable gel formulations: Potential drug carriers for the topical treatment of nail diseases. ( 26187167 )
2015
18
Psoriatic nail disease, a predictor of psoriatic arthritis. ( 25409998 )
2014
19
Potential use of optical coherence tomography and high-frequency ultrasound for the assessment of nail disease in psoriasis and psoriatic arthritis. ( 23988587 )
2013
20
Drug-related nail disease. ( 24079591 )
2013
21
Metoprolol-induced psoriatic nail disease. ( 22724586 )
2013
22
Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study. ( 23423871 )
2013
23
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. ( 24117389 )
2013
24
Iontophoresis for treating nail diseases. ( 23738661 )
2013
25
Assessment of psoriatic nail disease activity by rheumatologists: comment on the article by Lubrano et al. ( 22623218 )
2012
26
Patient assessments of skin, joint, and nail disease activity in psoriatic arthritis. ( 22383354 )
2012
27
Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. ( 22156725 )
2012
28
Nail disease in psoriatic arthritis: distal phalangeal bone edema detected by magnetic resonance imaging predicts development of onycholysis and hyperkeratosis. ( 22337245 )
2012
29
Optical coherence tomography: a new tool to assess nail disease in psoriasis? ( 21791896 )
2011
30
Nutrition and nail disease. ( 20620759 )
2010
31
Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. ( 21174373 )
2010
32
Clinical practice. Fungal nail disease. ( 19439745 )
2009
33
Psoriatic nail disease: quality of life and treatment. ( 19799826 )
2009
34
The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? ( 19424069 )
2009
35
Nail disease in pemphigus vulgaris. ( 19903430 )
2009
36
Management of psoriatic nail disease. ( 19341941 )
2009
37
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. ( 18083272 )
2008
38
Two case reports: treating common nail diseases and injuries. ( 17905360 )
2007
39
Therapies for psoriatic nail disease. A systematic review. ( 16724366 )
2006
40
Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be? ( 16546613 )
2006
41
Alefacept in the treatment of psoriatic nail disease: a proof of concept study. ( 16673801 )
2006
42
Nail diseases related to nail cosmetics. ( 16677969 )
2006
43
Childhood nail diseases. ( 16798433 )
2006
44
Drug-induced nail diseases. ( 16798438 )
2006
45
Alefacept in the treatment of psoriatic nail disease: a small case series. ( 15928640 )
2005
46
Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. ( 18360572 )
2005
47
Molecular genetics of hereditary hair and nail disease. ( 15468149 )
2004
48
Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked. ( 15113998 )
2004
49
One interpretation of a psychometric study of patients with nail disease. ( 12664041 )
2003
50
Observer agreement in recording the clinical signs of nail disease and the accuracy of a clinical diagnosis of fungal and non-fungal nail disease. ( 12653750 )
2003

Variations for Nail Disease

ClinVar genetic disease variations for Nail Disease:

6 (show all 13)
# Gene Variation Type Significance SNP ID Assembly Location
1 FZD6 NM_003506.3(FZD6): c.1750G> T (p.Glu584Ter) single nucleotide variant Pathogenic rs151339002 GRCh37 Chromosome 8, 104342091: 104342091
2 FZD6 NM_003506.3(FZD6): c.1750G> T (p.Glu584Ter) single nucleotide variant Pathogenic rs151339002 GRCh38 Chromosome 8, 103329863: 103329863
3 FZD6 NM_003506.3(FZD6): c.1531C> T (p.Arg511Cys) single nucleotide variant Pathogenic rs151339003 GRCh37 Chromosome 8, 104340634: 104340634
4 FZD6 NM_003506.3(FZD6): c.1531C> T (p.Arg511Cys) single nucleotide variant Pathogenic rs151339003 GRCh38 Chromosome 8, 103328406: 103328406
5 46;XY;inv(6)(p22q13)dn inversion Pathogenic
6 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic rs1553212868 GRCh37 Chromosome 1, 151378740: 151378740
7 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic rs1553212868 GRCh38 Chromosome 1, 151406264: 151406264
8 PKD1 NM_001009944.2(PKD1): c.226C> T (p.His76Tyr) single nucleotide variant Uncertain significance rs932577597 GRCh38 Chromosome 16, 2119368: 2119368
9 PKD1 NM_001009944.2(PKD1): c.226C> T (p.His76Tyr) single nucleotide variant Uncertain significance rs932577597 GRCh37 Chromosome 16, 2169369: 2169369
10 SETBP1 NM_015559.3(SETBP1): c.2614G> A (p.Gly872Arg) single nucleotide variant Likely pathogenic rs1555706928 GRCh38 Chromosome 18, 44951954: 44951954
11 SETBP1 NM_015559.3(SETBP1): c.2614G> A (p.Gly872Arg) single nucleotide variant Likely pathogenic rs1555706928 GRCh37 Chromosome 18, 42531919: 42531919
12 OFD1 NM_003611.2(OFD1): c.1999G> A (p.Ala667Thr) single nucleotide variant Uncertain significance rs1394450537 GRCh38 Chromosome X, 13760459: 13760459
13 OFD1 NM_003611.2(OFD1): c.1999G> A (p.Ala667Thr) single nucleotide variant Uncertain significance rs1394450537 GRCh37 Chromosome X, 13778578: 13778578

Expression for Nail Disease

Search GEO for disease gene expression data for Nail Disease.

Pathways for Nail Disease

Pathways related to Nail Disease according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 CARD9 CCR6 CLEC7A EGFR IL12RB1 IL17A
2
Show member pathways
13.61 CCR6 EGFR FZD6 IL12RB1 IL17A IL17RA
3
Show member pathways
13.1 EGFR IL12RB1 IL17A IL17F IL17RA STAT1
4
Show member pathways
12.95 CCR6 EGFR IL12RB1 IL17A IL17RA PLCD1
5
Show member pathways
12.95 CCR6 EGFR IL12RB1 IL17A IL17RA PLCD1
6
Show member pathways
12.32 IL12RB1 IL17A IL17F STAT1
7
Show member pathways
12.09 EGFR IL12RB1 IL17A IL17F STAT1
8 12.01 CARD9 CLEC7A STAT1
9
Show member pathways
11.99 CARD9 CLEC7A STAT1
10 11.96 EGFR FZD6 STAT1
11
Show member pathways
11.8 EGFR PLCD1 STAT1
12 11.69 IL17A IL17F STAT1
13 11.65 EGFR FZD6 PLCD1
14 11.62 EGFR IL12RB1 STAT1
15 11.4 CCR6 IL12RB1 IL17A
16
Show member pathways
11.37 IL12RB1 IL17A IL17F STAT1
17
Show member pathways
11.08 FZD6 RSPO4
18 10.96 EGFR STAT1
19 10.96 EGFR PLCD1 STAT1
20
Show member pathways
10.89 IL12RB1 IL17A IL17F IL17RA

GO Terms for Nail Disease

Biological processes related to Nail Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.71 IL12RB1 IL17A IL17F STAT1
2 defense response to fungus GO:0050832 9.48 IL17A IL17RA
3 positive regulation of defense response to virus by host GO:0002230 9.46 IL12RB1 STAT1
4 positive regulation of interleukin-6 secretion GO:2000778 9.43 IL17A IL17F
5 positive regulation of interleukin-23 production GO:0032747 9.37 IL17A IL17RA
6 fibroblast activation GO:0072537 9.32 IL17A IL17RA
7 regulation of interleukin-6 biosynthetic process GO:0045408 9.26 CARD9 IL17F
8 regulation of interleukin-2 biosynthetic process GO:0045076 9.16 CARD9 IL17F
9 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.13 IL17A IL17F IL17RA
10 interleukin-17-mediated signaling pathway GO:0097400 8.8 IL17A IL17F IL17RA

Sources for Nail Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....